Literature DB >> 10376128

Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.

R E See1, A A Fido, M Maurice, M M Ibrahim, G M Salama.   

Abstract

BACKGROUND: Previous studies have shown an increase in plasma levels of norepinephrine (NE) after clozapine treatment of schizophrenia. This effect has been suggested to relate to improvement in symptoms.
METHODS: To test whether other novel antipsychotic drugs have such an effect, the present experiment examined schizophrenic symptoms and plasma levels of NE before and after 5 weeks of treatment with risperidone or haloperidol.
RESULTS: Risperidone, but not haloperidol, significantly increased plasma NE; however, there was no correlation of this effect with clinical improvement on any symptom scale.
CONCLUSIONS: This finding suggests that risperidone shares similar properties with clozapine in enhancing peripheral NE, but that these changes in plasma NE may not be a consistent indicator of atypical antipsychotic drug efficacy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376128     DOI: 10.1016/s0006-3223(98)00199-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.

Authors:  Megan Beauchemin; Ramaz Geguchadze; Anyonya R Guntur; Kathleen Nevola; Phuong T Le; Deborah Barlow; Megan Rue; Calvin P H Vary; Christine W Lary; Katherine J Motyl; Karen L Houseknecht
Journal:  Pharmacol Res       Date:  2019-12-23       Impact factor: 7.658

2.  Allostatic load and reduced cortical thickness in schizophrenia.

Authors:  Joshua Chiappelli; Peter Kochunov; Anya Savransky; Feven Fisseha; Krista Wisner; Xiaoming Du; Laura M Rowland; L Elliot Hong
Journal:  Psychoneuroendocrinology       Date:  2016-11-24       Impact factor: 4.905

3.  Fornix Structural Connectivity and Allostatic Load: Empirical Evidence From Schizophrenia Patients and Healthy Controls.

Authors:  Anya Savransky; Joshua Chiappelli; Laura M Rowland; Krista Wisner; Dinesh K Shukla; Peter Kochunov; L Elliot Hong
Journal:  Psychosom Med       Date:  2017-09       Impact factor: 4.312

4.  Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.

Authors:  Yvette E Savoy; Michael A Ashton; Matthew W Miller; Frank M Nedza; Douglas K Spracklin; Mark H Hawthorn; Hans Rollema; F Fatima Matos; Eva Hajos-Korcsok
Journal:  Schizophr Bull       Date:  2008-08-14       Impact factor: 9.306

Review 5.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Desipramine enhances the ability of paliperidone to decrease alcohol drinking.

Authors:  David T Chau; Jibran Y Khokhar; Danielle Gulick; Ree Dawson; Alan I Green
Journal:  J Psychiatr Res       Date:  2015-07-18       Impact factor: 4.791

7.  Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

Authors:  Danielle Gulick; David T Chau; Jibran Y Khokhar; Ree Dawson; Alan I Green
Journal:  Psychiatry Res       Date:  2014-05-04       Impact factor: 3.222

8.  Internet-based search of randomised trials relevant to mental health originating in the Arab world.

Authors:  Yahya Takriti; Hany G El-Sayeh; Clive E Adams
Journal:  BMC Psychiatry       Date:  2005-07-26       Impact factor: 3.630

9.  Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.

Authors:  Giulio Scigliano; Gabriele Ronchetti
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

10.  Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia.

Authors:  Reiji Yoshimura; Hikaru Hori; Asuka Katsuki; Kiyokazu Atake; Jun Nakamura
Journal:  Ann Gen Psychiatry       Date:  2016-01-14       Impact factor: 3.455

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.